(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 9 December 2004 (09.12.2004)

(10) International Publication Number WO 2004/105758 A1

- (51) International Patent Classification⁷: A61K 31/4439, A61P 43/00
- (21) International Application Number:

PCT/GB2004/002238

- (22) International Filing Date: 26 May 2004 (26.05.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0312425.2

30 May 2003 (30.05.2003) GB

- (71) Applicant (for all designated States except US): THE

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

BOOTS COMPANY PLC [GB/GB]; 1 Thane Road West, Nottingham NG2 3AA (GB).

(72) Inventors; and
(75) Inventors/Applicants (for US only): SUNDERRAJ, Palanskwamy [IN/CH]; Bachstrasse 11, CH-8162 Steinmur (CH). SHEPHARD, Adrian [GB/GB]; 44 Leicester Street, Long Eaton, Nottingham NG0 17 (IGB). JONES, Huw [GB/GB]; 34 Archer Crescent, Wollaton, Nottingham NG8 1HB (GB).

(74) Agents: WALSH, David, P. et al.; Appleyard Lees, 15 Clare Road, Halifax HX1 2HY (GB).

(75) Abstract: There is disclosed the use of a consumable film comprising triprolidine for engalar issue of the PCT Gazene.

(76) Abstract: There is disclosed the use of a consumable film comprising triprolidine. Use of a consumable film comprising triprolidine as active ingredient in the manufacture of a composition for the treatment of Sleep disorders is also described. A method of treating such an individual with triprolidine. Use of a consumable film comprising triprolidine as active ingredient in the manufacture of a composition for the treatment of Sleep disorders is also described. A method of treating such an individual with triprolidine. Use of a consumable film comprising triprolidine as active ingredient in the manufacture of a composition for the treatment of Sleep disorders is also described. A method of treating seep of a person suffering from a sleep disorder, which method comprises administration of a consumable film comprision of triprolidine as active ingredient to such a person is also described. The administration of a consumable film comprision are active. of triprolidine as active ingredient to such a person is also described. The triprolidine is administered shortly before a person wishes to fall asleep, preferably orally and most commonly in the form of a tablet containing up to 20 mg, e.g. 0.1 mg, 1.25 mg or 2.5 mg, of the active ingredient. The triprolidine is also effective in enabling an individual to sleep more easily.

